Physician profile
Arthur Strzepka
NPI 1821625625
$8,604.17
in general payments reported to CMS, 2019-2025
19 companies · $4,624 in 2025
The $4,624 reported for 2025 was more than what 98% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $424 · 2024: $3,555 · 2025: $4,624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,399 · Travel and Lodging: $3,205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,399.38 |
| Travel and Lodging | $3,204.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $6,519.57 | 2023-2025 | Intracept, Wavewriter Alpha Prime 16, General - Therapies |
| Saluda Medical Americas, INC. | $644.98 | 2025 | Evoke |
| Si-Bone, INC. | $214.68 | 2024-2025 | |
| Nalu Medical, INC. | $184.15 | 2025 | Nalu Neurostimulation System |
| Abbvie INC. | $167.18 | 2023-2025 | Botox, Ubrelvy, Qulipta |
| Spr Therapeutics, INC | $120.81 | 2024 | Sprint Pns System |
| Vertex Pharmaceuticals Incorporated | $110.36 | 2024-2025 | |
| Relievant Medsystems, INC. | $102.53 | 2023 | Intracept |
| Spinal Simplicity, LLC | $101.74 | 2025 | Ha Minuteman G3-R |
| Ibsa Pharma INC. | $69.77 | 2023-2024 | Tirosint, Licart, Tirosint |
| Depuy Synthes Sales INC. | $68.95 | 2024-2025 | Monovisc, Orthovisc |
| Pfizer INC. | $64.67 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $52.02 | 2023-2025 | Belbuca, Nucynta |
| Scilex Pharmaceuticals INC. | $47.46 | 2023-2024 | Ztlido |
| Vertos Medical, INC. | $36.29 | 2024 | Mild Device Kit |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| International Rehabilitative Sciences, INC | $29.87 | 2023 | Rs 4i Plus Sequential Stimulator |
| Nevro Corp. | $26.20 | 2024 | Senza |
| Neurocrine Biosciences, INC. | $22.88 | 2024 | Ingrezza |
| Novo Nordisk INC | $20.06 | 2023 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Strzepka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.